Skip to main content
Premium Trial:

Request an Annual Quote

Agilent, Signature Genomic Ink Oligo Microarray Supply Agreement

NEW YORK (GenomeWeb News) – Agilent Technologies will supply microarrays to Signature Genomic Laboratories and its customers under a new long-term agreement, Signature said today.
 
Under the agreement, Agilent will supply Signature and customers using the SignatureChip Oligo Solution with its custom oligonucleotide microarrays, the Spokane, Wash.-based company said.
 
The SignatureChip OS is used in detecting chromosome abnormalities in individuals with mental retardation/developmental delay, autism, and congenital abnormalities.
 
The company said the agreement also allows users of its Genoglyphix software to use the oligo arrays in their research applications.
 
Signature offers its microarray-based cytogenetic diagnostic and chromosome analysis products to clinical geneticists, neurologists, pediatricians, and other physicians and researchers.
 
Financial terms of the agreement were not released.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.